4D Molecular Therapeutics Inc (FDMT NASDAQ) stock market data APIs
$10.6555
0.09(0.8%)
as of August 7, 2026
Try our APIs with
free plan!
4D Molecular Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Prev. Close
10.6555
Open
10.7443
High
10.9103
Low
10.4737
52 wk Range
5.3301-14
Market Cap
552 M
Shares Outstanding
52 276 K
Revenue
88 242 K
Beta
2.69
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with 4D Molecular Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get 4D Molecular Therapeutics Inc data using free add-ons & libraries
Get 4D Molecular Therapeutics Inc Fundamental Data
4D Molecular Therapeutics Inc Fundamental data includes:
- Net Revenue: 88 242 K
- EBITDA: -171 434 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get 4D Molecular Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-10
- EPS/Forecast: -1.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
4D Molecular Therapeutics Inc News
New
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago. Thes...
4D Reports Positive 2-Year Phase 2b Data For 4D-150 In Wet AMD
(RTTNews) - 4D Molecular Therapeutics, Inc. (FDMT), a late-stage biotechnology company, announced positive 2-year data from the Phase 1/2 PRISM trial, including a Phase 2b cohort evaluating 4D-150 in ...
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerat...
Get 4D Molecular Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
